Journal
HUMAN MOLECULAR GENETICS
Volume 18, Issue -, Pages R75-R83Publisher
OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddp010
Keywords
-
Funding
- UK Medical Research Council
- EU
- Leukaemia Research Fund
- Wellcome Trust
- Fidelity Foundation
- MRC [MC_U117527252, G0601056] Funding Source: UKRI
- Medical Research Council [MC_U117527252, G0601056] Funding Source: researchfish
Ask authors/readers for more resources
Down syndrome (DS) is caused by trisomy of chromosome 21 (Hsa21) and is associated with a number of deleterious phenotypes, including learning disability, heart defects, early-onset Alzheimer's disease and childhood leukaemia. Individuals with DS are affected by these phenotypes to a variable extent; understanding the cause of this variation is a key challenge. Here, we review recent research progress in DS, both in patients and relevant animal models. In particular, we highlight exciting advances in therapy to improve cognitive function in people with DS and the significant developments in understanding the gene content of Hsa21. Moreover, we discuss future research directions in light of new technologies. In particular, the use of chromosome engineering to generate new trisomic mouse models and large-scale studies of genotype-phenotype relationships in patients are likely to significantly contribute to the future understanding of DS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available